Study Title: Phase 3 Randomized Open-label Study of Adjuvant Pembrolizumab W/WO MK2870 in Resectable Stages II-IIIB(N2) NSCLC for Patients not Achieving pCR After Receiving Neoadjuvant Pembrolizumab with Platinum-Based Doublet Chemotherapy Followed by Surgery
For more information about the trial above please contact the study team:Medical University of South CarolinaPrincipal Investigator, Alexander, Mariam, at alexanma@musc.edu.Study Coordinator, Schumpp, Alec, at schumpp@musc.edu.Trial opened at the following institutions: Medical University of South Carolina